Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL

David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.

David J. Andorsky, MD, medical oncologist and hematologist, Rocky Mountain Cancer Centers, associate chair, US Oncology Hematology Research, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the community setting in the United States, and how social determinants of health may have affected these outcomes.

Related Content:

ASH Annual Meeting and ExpositionOncLive TVConferenceNon-Hodgkin Lymphoma
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer
Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC
Dr Phillips on the Evolution of the MCL Treatment Paradigm